What Does MeiraGTx Do?

Total employees383
HeadquartersLondon
Founded2015

MeiraGTx Holdings plc (NASDAQ: MGTX) is a vertically integrated, clinical-stage gene therapy company with multiple programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization, gene therapy manufacturing, and a potentially transformative gene regulation technology. The company is focused on developing curative treatments for patients living with serious diseases, initially targeting conditions affecting the eye, central nervous system, and salivary gland, with plans to expand into other areas of unmet medical need.

Where Is MeiraGTx's Headquarters?

HQ Function

Serves as the central hub for corporate governance, strategic leadership, global operations management, and investor relations for MeiraGTx.

Notable Features:

Strategically situated in a global financial and life sciences hub, providing access to international talent, collaborators, and capital markets.

Work Culture:

Characterized by a strong emphasis on scientific innovation, collaboration, and a patient-first approach. The culture fosters cutting-edge research and development in the field of gene therapy.

HQ Significance:

The London headquarters is key for coordinating MeiraGTx's international research efforts, clinical trial management, and commercialization strategies, benefiting from the UK's robust biotech ecosystem.

Values Reflected in HQ: The headquarters' location and function reflect MeiraGTx's commitment to global impact, scientific excellence, and strategic growth in the competitive biopharmaceutical landscape.

Location:

MeiraGTx maintains a strategic global presence with its principal executive office in London (UK), significant research and operational facilities in New York (USA), and a specialized gene therapy manufacturing plant in Shannon (Ireland). This international structure enables the company to conduct global clinical trials, foster research partnerships, and prepare for potential commercial activities across North America, Europe, and other key markets.

Street Address:

9 Marylebone Lane

City:

London

State/Province:

England

Country:

United Kingdom

Where Else Does MeiraGTx Operate Around the World?

New York, NY, USA

Address: 430 East 29th Street, Suite 1140, New York, NY 10016, USA

Facilitates access to U.S. capital markets, leading research institutions, clinical trial sites, and engagement with U.S. regulatory authorities like the FDA.

Shannon, Co. Clare, Ireland

Address: Western Business Park, Shannon, Co. Clare, Ireland

Leverages Ireland's established biopharmaceutical manufacturing infrastructure, skilled workforce, and supportive regulatory environment. Enables in-house control over a crucial part of the gene therapy supply chain.

Buying Intent Signals for MeiraGTx

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading MeiraGTx? Meet the Executive Team

As of April 2025, MeiraGTx' leadership includes:

Alexandria Forbes, Ph.D. - President and Chief Executive Officer
Richard Giroux - Chief Operating Officer and Chief Financial Officer
Stuart M. Arbuckle - Chief Commercial Officer
Robert K. Zeldin, M.D. - Chief Medical Officer
Michel Farah, Ph.D. - Chief Technical Officer
Scott L. Potasman - General Counsel and Corporate Secretary

Who's Investing in MeiraGTx?

MeiraGTx has been backed by several prominent investors over the years, including:

Perceptive Advisors
OrbiMed Advisors
RTW Investments, LP
BlackRock
Vanguard Group
Johnson & Johnson Innovation - JJDC, Inc.

What Leadership Changes Has MeiraGTx Seen Recently?

Hire1
Exits0

In the past 12 months (relative to early 2024), MeiraGTx notably strengthened its commercial leadership with the appointment of Stuart M. Arbuckle as Chief Commercial Officer in May 2023. No other significant C-suite departures or appointments have been publicly highlighted, suggesting leadership stability.

New Appointments:

Stuart M. Arbuckle, Stuart M. Arbuckle joined MeiraGTx as Chief Commercial Officer, bringing extensive experience to lead the company's commercialization efforts for its advancing gene therapy programs.

What Technology (Tech Stack) Is Used byMeiraGTx?

Discover the tools MeiraGTx uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

MeiraGTx Email Formats and Examples

MeiraGTx likely follows standard corporate email address patterns. Common formats include using the first initial and last name, or first name separated by a period from the last name, followed by '@meiragtx.com'.

[first_initial][last]@meiragtx.com (e.g., jdoe@meiragtx.com) or [first].[last]@meiragtx.com (e.g., jane.doe@meiragtx.com)

Format

aforbes@meiragtx.com

Example

80%

Success rate

What's the Latest News About MeiraGTx?

GlobeNewswireFebruary 29, 2024

MeiraGTx Announces Fourth Quarter and Full Year 2023 Financial and Operational Results

MeiraGTx reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on its clinical programs and business operations, including progress in its ophthalmology, salivary gland, and neurodegenerative disease pipelines....more

GlobeNewswireJanuary 8, 2024

MeiraGTx Provides Update on Phase 2 AQUAx Study of AAV-hAQP1 for Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx provided an update on its Phase 2 AQUAx clinical trial evaluating AAV-hAQP1 for the treatment of Grade 2/3 radiation-induced xerostomia, highlighting ongoing patient enrollment and study progress....more

GlobeNewswireNovember 9, 2023

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

The company announced its financial results for the third quarter of 2023 and provided updates on its various gene therapy programs, including advancements in clinical trials and manufacturing capabilities....more

GlobeNewswireMay 2, 2023

MeiraGTx Appoints Stuart M. Arbuckle as Chief Commercial Officer

MeiraGTx announced the appointment of Stuart M. Arbuckle as Chief Commercial Officer, tasked with developing and executing the company's global commercial strategy for its gene therapy candidates....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including MeiraGTx, are just a search away.